Campbell Prostate Cancer + NCCN 2.2021 Flashcards

1
Q

The American Brachytherapy Society guidelines suggest that prostate glands that are greater than ___ are technically more difficult to implant because of: ___ and ___;

___ can reduce prostate volumes by ___ % to optimize gland before brachytherapy

A

60cm
- increased frequency of pubic arch interference - large number of seeds required

Cytoreductive ADT
25% to 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prostate volumes in excess of ___ may require ___ before RT to reduce volume of rectum or bladder exposed to radiation.

A

Neoadjuvant ADT for cytoreduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Transurethral resection of the prostate (TURP) ____ (before or after?) external radiation, rather than after, may be advisable for men in, or at risk of, retention.

A

BEFORE radiation!

** post-treatment transurethral resection is performed, there may be a higher associated risk of incontinence (Polland et al., 2017), particularly after brachytherapy with up to 18% of men incontinent after TURP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Contraindications to RT for prostate cancer

A

Previous radical pelvic irradition
Previous pelvic surgery: potentially trap bowel within pelvic field
PResence of substantial or susceptible bowel (hernia ex.)
Poor tissue healing (chronic steroid therapy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk strat:

Very low

A

• T1c AND
• Gleason score ≤6/grade group 1 AND
• PSA <10 ng/mL AND
• Fewer than 3 prostate biopsy fragments/cores
positive, ≤50% cancer in each fragment/core AND
• PSA density <0.15 ng/mL/g

Imaging: NOT indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Risk strat:

Low

A
  • T1–T2a AND
  • Gleason score ≤6/grade group 1 AND
  • PSA <10 ng/mL

Imaging: NOT indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Risk strat:

Favorable intermediate

A
  • T2b–T2c OR
  • Gleason score 3+4=7/grade group 2 OR
  • PSA 10–20 ng/mL AND
  • Percentage of positive biopsy cores <50%

Imaging:
• Bone imaging: not recommended for staging
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph node involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk Strat:

Unfavorable intermediate

A

• T2b–T2c OR
• Gleason score 3+4=7/grade group 2 or Gleason
score 4+3=7/grade group 3 OR
• PSA 10–20 ng/mL

Imaging:

  • Bone imaging: recommended if T2 and PSA >10 ng/mL
  • Pelvic ± abdominal imaging: recommended if nomogram predicts >10% probability of pelvic lymph
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Risk strat:

High

A

• T3aOR
• Gleason score 8/grade group 4 or Gleason score
4 +5=9/grade group 5 OR
• PSA >20 ng/mL

Imaging:
• Bone imaging: recommended
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Risk strat:

Very high

A

• T3b–T4 OR
• Primary Gleason pattern 5 OR
• >4 cores with Gleason score 8–10/grade group 4
or 5

Imaging:
• Bone imaging: recommended
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Observation is most frequently employed in ___ .

General ffu consists of:

A

Men at low risk of prostate cancer death

Periodic PSA testing, clinical exam, use of imaging to monitor progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SURVEILLANCE should be recommended as the best care option for ___ and preferable care option for ___ localized prostate cancer.

A

best for VERY LOW RISK

preferable for LOW RISK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Death in men on active surveillance, most commonly from ___

A

Cardiovascular disease

** Rarely from prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Risk factors:

____ race found be associated withdverse pathologic outcomes such as positive surgical margins, upgrading, or upstaging.

A

African-American race

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

A history of ___ is significant and may reflect a germline disposition to prostate cancer.

A

A history of metastatic disease at a young age (<60) in a first-degree relative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Advising men to ____ is the single most cost-effective health intervention in the entire edifice of medical practice.

A

QUIT SMOKING!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Patients taking ___ in the SELECT trial had an increased risk of prostate cancer.

Patient consuming >=140 micrograms/day of supplemental ___ had 2.6 times greater disease-specific mortality.

A

Vitamin E

Selenium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lifestyle recommendations for active surveillance: ___

A
  1. Exercise regularly, and include vigorous activity if possible.
  2. Maintain a healthy weight.
  3. Stop smoking.
  4. Eat a vegetable- and grain-based diet; moderate red meat consump-
    tion, especially processed meats; if eating meat, rely on fish and
    skinless poultry.
  5. Limit saturated fat intake.
  6. Take vitamin D, 1000 to 2000 IU/day, especially during periods
    of reduced sunlight.
  7. Consider a low-dose statin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IMRT

A

Intensity-modulated radiation therapy

IMRT employs more complex, dynamic beam shapes wherein the intensity of radiation is varied across the beam (as opposed to uniform intensity across the beam in 3DCRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Low-dose-rate Brachytherapy

A

Permanent seed implantation: Delivers a dose over a number of weeks to months depending on the isotope chosen, hence the term low- dose-rate

125Iodine emits low-energy x-rays at 27 keV, with a half-life of 59.6 days.

103Palladium was introduced in 1986 because it has an energy spectrum similar to that of 125I, with 21-keV x-rays, but with a significantly shorter half-life of 17 days.

131Cesium, which emits x-rays at 30 keV (thereby offering dose characteristics similar to 125I)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

High-dose-rate Brachytherapy

A

Delivers short but high doses of radiation using temporary catheters

Hollow catheters are placed through the perineum into the prostate using the same procedure as for LDR brachytherapy

iridium-192 (192Ir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Advantages of HDR vs. LDR Brachytherapy:

A

The use of catheters allows for more ready inclusion of extracapsular
disease and seminal vesicles, if desired.
• There is greater opportunity for dose optimization by modifying
dwell times and positions of the source within the catheters.
• The use of high doses per fraction has a potential biologic dose advantage for prostate cancer if a low alpha/beta ratio exists.
• No need for personnel to handle the radioactive source during
treatment.
• The use of a single source for all patients using a multipurpose
facility makes HDR brachytherapy potentially more cost-effective.
Potential disadvantages for HDR versus LDR brachytherapy include: • There are potential treatment inaccuracies caused by catheter and organ/patient movement between imaging and time of source insertion (during treatment planning) or between fractions, interobserver contouring variabilities, and effects of edemaThe relatively high activity and energy of the 192Ir source requires
availability of a shielded room for treatment delivery.
• There are less favorable pathologic response results from avail- able post-treatment biopsy studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Major acute toxicity of brachytherapy is ___

A

Obstructive and irritative uropathy

Low but non-negligible risk of need for temporary catheterization.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Relative contraindications to brachytherapy:

A

Large TURP defects, TURP within prior 3-6months
Factors assoc. with poor urinary outcomes or obstruction: Qmax < 10, IPSS >20, large median lobe
Prior pelvic RT
Connective tissue disease or IBD
Pubic arch interference
Lithotomy position
Rectal fistula or lack of TRUS access

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The most important pathologic criteria predicting prognosis after radical prostatectomy are:

A
Gleason score
Surgical margin status, 
Extracapsular extension
Seminal vesicle invasion
Lymph node involvement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Many men with clinical stage T3 disease have ____ and may not benefit from prostatectomy.

Select (low-volume disease) may benefit because local control may be achieved in most.

A

Regional spread

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

The presence of ___ increases progression from 7% to 18-35% at 5 years.

A

Focal or established extracapsular extension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Radical prostatectomy alone can result in disease-free survival in ___ despite clinically advanced disease.

A

At least one-half of men at 8 to 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

____ therapy before radical prostatectomy does NOT appear to improve DSS or OS.

A

Neoadjuvant androgen deprivation (NAD)

** For locally advanced tumors (specifically cT3), current data, both retrospective and prospective, do not support a significant benefit of NAD before surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The use of adjuvant RT is associated with ___.

Early use of ___ may be beneficial for advanced tumors at the time of biochemical recurrence in select patients.

A

A range of BDFS (biochemical disease free survival) from 50% to 88% at 5 years

secondary therapy (RT or AD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Men with seminal vesicle invasion who achieve a low PSA level (<0.3 ng/mL) after prostatectomy or have positive surgical margins may benefit more from ___.

men with more advanced disease never reaching an undetectable PSA level generally constitute a poor prognostic group likely harboring ___.

A

Adjuvant RT.

Unrecognized lymph node or distant disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Postradiation PSA “bounce”

NOT ALL MEN ARE DESTINED FOR BIOCHEMICAL

A

Varied definition: elevated PSA of 0.1 ng/mL to 0.5 ng/mL over the prebounce PSA with a subsequent decrease in PSA.

Occurred at a mean time of 9 months

Associated with an improvement in biochemical recurrence–free survival compared with those who did not have a bounce

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Patients selected for salvage RP must have the ff: ___

A

Biopsy-proven radiorecurrent prostate cancer

At least 10 years of life expectancy

Lack of identifiable metastasis on imaging

PSA of less than 10 ng/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

All current forms of hormonal therapy in PCA function by: ___

A

Reducing the ability of androgen to activate the AR

** by lowering androgen levels, decreasing conversion of testosterone to more potent DHT, or blocking androgen-AR binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

___ is overexpressed in 20-30% of CRPC metastases.

A

AR gene

** enhances response to low levels of endogenous androgens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

AR mutations and splice variants:

___ predominant splice variant has been strongly associated with castration resistance and overall poor patient survival

A

AR-V7

37
Q

GnRH agonists

A

Leuprolide
Goserelin
Triptorelin

SOA: Pituitary
MOA: Stimulates release of LH; feedback loop ultimately decreases LH production

Mainstay of therapy for metastatic disease; leads to increase in FSH; considerable side effects

38
Q

GnRH antagonists

A

Degarelix
Abarelix
Cetrorelix

SOA: Pituitary
MOA: Binds to receptors and blocks release of GnRH

Prevents testosterone surge; leads to decrease in FSH; considerable side effects

39
Q

Adrenal-targeting drugs

A

Ketoconazole Abiraterone Oreteronel (TAK-700)
Galeterone

SOA: Adrenal
MOA: Decreases androgen production from steroid precursors by blocking cytochrome P450 enzymes

Selective CYP17 inhibitors administered with low-dose prednisone; side effects can include hypertension, edema, and hypokalemia

40
Q

1st generation AR antagonists

A

Flutamide Nilutamide Bicalutamide

SOA: Prostate, PCA
MOA: Nonsteroidal antiandrogen inhibits binding of testosterone and DHT to the AR

Monotherapy not indicated; associated with gynecomastia

41
Q

2nd generation AR antagonists

A

Enzalutamide Apalutamide

SOA: Prostate, PCA
MOA: Blocks AR, minimizes nuclear translocation of AR, and diminishes AR-mediated transcription

Associated with falls, fatigue, and decreased appetite

42
Q

5alpha-reductase inhibitors

A

Finasteride (type II isoenzyme inhibition)
Dutasteride (type I and II isoenzyme inhibition)

SOA: Prostate, PCA
MOA: Inhibits the conversion of testosterone to DHT

Commonly administered for BPH; not indicated for prostate cancer management

43
Q

Four approaches for androgen blockade:

A

(1) surgical removal of the testicles (orchiectomy),
2) AR antagonism,
(3) inhibition of LHRH and/or LH, and
(4) inhibition of androgen synthesis

44
Q

About one-quarter of men on ___ therapy note a delayed adaptation to darkness after exposure to bright illumination.

A

NIlutamide

** Effects reversible with cessation

45
Q

Most common side effects of enzalutamide: ___

A

Fatigue, breast enlargement/tenderness, diarrhea, and hot flashes.

** Seizures were more common in men taking enzalutamide compared with placebo but occurred in less than 1%

46
Q

Common side effects of apalutamide: ___

A

25% of men Experienced a rash, 12% experienced falls and fractures, and 8% had hypothyroidism

47
Q

In a review of 24 trials involving more than 6600 patients, survival after therapy with ___ was equivalent to orchiectomy

A

An LHRH agonist

*** flare of LH and testosterone levels, resulting in a severe, life-threatening exacerbation of symptoms, almost exclusively occurring in men with metastases in the spine or weight-bearing regions

48
Q

Aminoglutethimide

A

Blocks production of aldosterone and cortisol. As the medical version of a total adrenalectomy, the use of this agent requires replacement of cortisone and fludrocortisone

*** Side effects include anorexia, nausea, skin rash, lethargy, vertigo, hypothyroidism, and nystagmus.

49
Q

Abiraterone side effects include: ___ which are due to: ___ and may be prevented by: ___

A

Hypokalemia, hypertension, and fluid overload

Increase in the mineralocorticoids deoxycorticoste- rone and corticosterone

Co-administration of prednisone (5 mg one to two times daily) suppresses the ACTH increase and lowers the likelihood of mineralocorticoid excess

50
Q

LATITUDE trial showed that ___ + ___ was superior to traditional ADT by ___.

A

Abiraterone + prednisone was superior to traditional ADT

Extending median radiographic progression-free survival and overall survival

51
Q

VERY LOW RISK management

>20 y EPS

A

AS

OR

EBRT or brachytherapy

OR

RP
- Adverse features: EBRT +- ADT or observation

52
Q

VERY LOW RISK

10-20 y EPS

A

AS

53
Q

VERY LOW RISK

<10 y EPS

A

Observation

54
Q

LOW RISK

>=10 y EPS

A

AS

OR

EBRT or brachytherapy

OR

RP
- Adverse features: EBRT +- ADT or observation

55
Q

LOW RISK

<10 y EPS

A

Observation

56
Q

FAVORABLE INTERMEDIATE

>10 y

A

AS

OR

EBRT or brachytherapy ALONE

OR

RP +/- PLND if >= 2% prob of LN mets

  • AF, no LN: EBRT +- ADT or observation
  • LN mets: ADT (cat 1) +- EBRT (cat 2b) or observation
57
Q

FAVORABLE INTERMEDIATE

5-10 y EPS

A

EBRT or brachytherapy ALONE

OR

Observation

58
Q

UNFAVORABLE INTERMEDIATE

>10 y EPS

A

RPp ± PLND if predicted probability of lymph node metastasis ≥2%

OR

EBRTo + ADTt (4–6 mo)
or
EBRTo + brachytherapyo ± ADTt (4–6 mo)

59
Q

UNFAVORABLE INTERMEDIATE

5-10 y EPS

A

EBRTo + ADTt (4–6 mo)
or
EBRTo + brachytherapyo ± ADTt (4–6 mo)

OR

Observation (PREFERRED)

60
Q

HIGH/VERY HIGH RISK

> 5 y or symptomatic

A

EBRTo + ADTt (1.5–3 y; category 1) ± docetaxel (for very high risk only)

OR

EBRTo + brachytherapyo + ADTt (1–3 y; category 1 for ADT)

OR

RPp + PLND

61
Q

HIGH/VERY HIGH RISK

≤5 y and asymptomatic

A

Observationq
or

ADT
or

EBRT

62
Q

Active surveillance (AS) components:

A

• Consider confirmatory prostate biopsy with or without mpMRI and with or without
molecular tumor analysisj to establish candidacy for active surveillancen
• PSA no more often than every 6 mo unless clinically indicated
• DRE no more often than every 12 mo unless clinically indicated v
• Repeat prostate biopsy no more often than every 12 mo unless clinically indicated
• Repeat mpMRI no more often than every 12 mo unless clinically indicated

63
Q

Observation

A

involves monitoring the course of disease with the expectation to deliver palliative therapy for the development of symptoms or a change in exam or PSA that suggests symptoms are imminent

64
Q

Adverse features

A

Positive margin(s); seminal vesicle invasion; extracapsular extension; or detectable PSA

65
Q

PSA nadir

A

PSA nadir is the lowest value reached after EBRT or brachytherapy

66
Q

PSA persistence/recurrence after RP

A

Failure of PSA to fall to undetectable levels (PSA persistence) or undetectable PSA after RP with a subsequent detectable PSA that increases on 2 or more determinations (PSA recurrence).

67
Q

RTOG-ASTRO (Radiation Therapy Oncology Group - American Society for Therapeutic Radiology and Oncology) Phoenix Consensus

A

1) PSA increase by 2 ng/mL or more above the nadir PSA is the standard definition for PSA persistence/ recurrence after EBRT with or without HT; and 2) A recurrence evaluation should be considered when PSA has been confirmed to be increasing after radiation even if the increase above nadir is not yet 2 ng/mL, especially in candidates for salvage local therapy who are young and healthy.

68
Q

REGIONAL RISK GROUP (ANY T, N1,M0)

>5 y or symptomatic

A

EBRTo + ADTt (preferred) ± abirateroneee,ff

OR

ADTt ± abirateronet,ee

69
Q

REGIONAL RISK GROUP (ANY T, N1,M0)
≤5 y
and asymptomatic

A

Observationq or t

ADT

70
Q

MONITORING: RECURRENCE

After initial definitive therapy

A
  • PSA every 6–12 mo for 5 y,gg then every year
  • DRE every year, but may be omitted if PSA undetectable

If with: Radiographic evidence of metastatic disease without PSA persistence/recurrence –> BIOPSY

71
Q

MONITORING: RECURRENCE
N1 on ADT
or
Localized on observation

A
  • Physical exam + PSA every 3–6 mo
  • Imaging for symptoms or increasing PSAf

Check for PROGRESSION: N1, m0 or m1

72
Q

POST-RP PSA Persistence/recurrence

A
Risk stratificationjj PSADT
Consider:
• Bone imagingf,kk
• Chest CT
• Abdominal/pelvic CT or
abdominal/pelvic MRIf • C-11 choline or F-18
fluciclovine PET/CT or
PET/MRIf,w,ll
• Prostate bed biopsy
  (especially if imaging suggests local recurrence

IF: Studies negative for distant metastases or imaging not performed –> EBRTo ± ADTt or Observationq –> then monitor for progression

73
Q

PSA persistence/ recurrencey or

Positive DRE

A
• Risk stratificationmm
PSADT
• Bone imagingf,kk • Prostate MRI
• Transrectal
ultrasound (TRUS)
biopsy
• Consider: Chest CT Abdominal/pelvic CT or abdominal/
 pelvic MRIf C-11 choline or
 F-18 fluciclovine
PET/CT or PET/ MRIf,ll

TRUS biopsy positive, studies negative
for distant metastases –> >10y LIFE EXPECTANCY – > Observationq or p
RP + PLND
or o Brachytherapy or
High-intensity focused ultrasound (HIFU) (category 2B) or cryotherapy

TRUS negative or <10 y EPS: Observation or ADT

74
Q

M0-CASTRATION NAIVE SYSTEMIC THERAPY

A

Observation

OR

ADT

Then: Physical exam + PSA every 3–6 mo
• Imaging for symptoms
• Consider periodic imaging for patients with
M1 to monitor treatment response

75
Q

M1-CASTRATION NAIVE SYSTEMIC THERAPY

A

ADTt with one of the following: • Preferred regimens:
Apalutamide (category 1)t
Abiraterone (category 1)t,ee
Docetaxel 75 mg/m2 for 6 cyclesuu (category 1)vv Enzalutamide (category 1)t
• EBRTo to the primary tumor for low-volume M1uu
or ADT

Then: Physical exam + PSA every 3–6 mo
• Imaging for symptoms
• Consider periodic imaging for patients with
M1 to monitor treatment response

76
Q

M0-CRPC
Conventional imaging studies negative
for distant metastases

A

Continue ADTt to maintain castrate serum levels of testosterone (<50 ng/dL)

PSADT >10 mo: Observation (preferred)q
or
Other secondary t hormone therapy

PSADT ≤10 mo: Preferred regimens: • Apalutamidet
(category 1)
• Darolutamidet (category 1) t
• Enzalutamide (category 1)
Other recommended regimens:
• Other secondary t
77
Q

M1-CRPC
CRPC, conventional imaging studies positive
for metastases

A

• •

Metastatic lesion biopsyyy
Tumor testing for MSI-H or dMMR if not previouslyc performed Germline and tumor testing
for homologous recombination gene mutations if not previously performedc

• Continue ADTt to maintain castrate levels of serum testosterone (<50 ng/dL)
• Additional treatment options:
Bone antiresorptive therapy with denosumab (category 1, preferred) or zoledronic acid
if bone metastases
present o Palliative RT for painful
bone metastases Best supportive care

78
Q

SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA

NO PRIOR docetaxel/no prior novel hormone therapy

A

No prior docetaxel/no prior novel hormone therapyfff
• Preferred regimens Abirateronet,ggg (category 1hhh) Docetaxelaaa,iii (category 1) Enzalutamidet (category 1)
•Useful in certain circumstances
Sipuleucel-Taaa,jjj (category 1)
Radium-223kkk for symptomatic bone metastases (category 1)
•Other recommended regimens t Other secondary hormone therapy

79
Q

SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA

PRIOR docetaxel/no prior novel hormone therapy

A

• Preferred regimens Abirateronet, ggg (category 1) Cabazitaxelaaa Enzalutamidet (category 1)
• Useful in certain circumstances
Mitoxantrone for palliation in symptomatic patients who
cannot tolerate other therapiesaaa Cabazitaxel/carboplatinaaa,nnn aaa
Pembrolizumab for MSI-H or dMMR
Radium-223kkk for symptomatic bone metastases (category 1)
• Other recommended regimens Sipuleucel-Taaa,jjj t Other secondary hormone therapy

80
Q

SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA

Prior novel hormone therapy/No prior docetaxel

A

Prior novel hormone therapy/No prior docetaxelfff,lll • Preferred regimens aaa
Docetaxel (category 1)
Sipuleucel-Taaa,jjj
• Useful in certain circumstances mmm
Olaparib for HRRm (category 1) Cabazitaxel/carboplatinaaa,nnn aaa
Pembrolizumab for MSI-H or dMMR
Radium-223kkk for symptomatic bone metastases (category 1) Rucaparib for BRCAmooo
• Other recommended regimens Abirateronet,ggg ggg,ppp
Abiraterone +t dexamethasone Enzalutamide
Other secondary hormone therapy
t

81
Q

SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA

Prior docetaxel and prior novel hormone therapy

A

All systemic therapies are category 2B if visceral metastases are present)
• Preferred regimens
Cabazitaxelaaa (category 1hhh)
Docetaxel rechallengeaaa,eee
• Useful in certain circumstances hhh,mmm
Olaparib for HRRm (category 1) Cabazitaxel/carboplatinaaa,nnn aaa
Pembrolizumab for MSI-H or dMMR
Mitoxantrone for palliation in symptomatic patients who cannot
tolerate other therapiesaaa
Radium-223kkk for symptomatic bone metastases (category 1hhh) Rucaparib for BRCAmooo
• Other recommended regimens Abirateronet,ggg
Enzalutamidet t

82
Q

An extended PLND

A

removal of all node-bearing tissue from an area bound by the external iliac vein anteriorly, the pelvic sidewall laterally, the bladder wall medially, the floor of the pelvis posteriorly, Cooper’s ligament distally, and the internal iliac artery proximally.

83
Q

Men with high-volume, ADT-naïve, metastatic disease should be considered
for ___

A

ADT and docetaxel

84
Q

Immunotherapy considered for: ___

A

Men with Asymptomatic or minimally symptomatic mCRPC may consider
immunotherapy.

85
Q

Sipuleucel-T is only for: ___

A

nly for asymptomatic or minimally symptomatic, no liver metastases, life expectancy >6 months, ECOG performance status 0–1.
Sipuleucel-T is not recommended for patients with small cell/ neuroendocrine prostate cancer.

86
Q

Pembrolizumab (MSI-H or DMMR) only as ___.

A

subsequent Systemic therapy for patients with metastatic CRPC who have progressed through prior docetaxel and/or a novel hormone therapy.

87
Q

For prevention of SREs in CRPC: ___ and ___

A

Denosumab (SUPERIOR) and
zoledronic acid have been shown to prevent disease-related skeletal complications, which include fracture, spinal cord compression, or the need for surgery or RT to bone.

Denosumab (preferred) is given subcutaneously every 4 weeks.
Zoledronic acid is given intravenously every 3 to 4 weeks or every 12 weeks.

Zoledronic acid is not recommended for creatinine clearance <30 mL/min.

88
Q

Osteonecrosis of the jaw (ONJ)

A

Seen with both agents; risk is increased in patients who have tooth extractions, poor dental hygiene, or a dental appliance. referred
for dental evaluation before starting either zoledronic acid or denosumab.